alexa
Reach Us +441467840001
A Rational Approach towards the Development of Human Carbonic Anhydrase Inhibitors as Antiepileptic Agent | OMICS International
ISSN: 2161-0444
Medicinal Chemistry

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A Rational Approach towards the Development of Human Carbonic Anhydrase Inhibitors as Antiepileptic Agent

Kalyan K Sethi1*, Prasanta K Nayak2, Hindol Sarkar1 and Saurabh M Verma1

1Department of Pharmaceutical Science and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India

2Department of Pharmacology, Himalayan Pharmacy Institute, Majhitar, Sikkim, India

*Corresponding Author:
Kalyan K Sethi
Department of Pharmaceutical Science and Technology
Birla Institute of Technology, Mesra, Ranchi-835 215, Jharkhand, India
Tel: +918987511080
Fax: +916512275401
E-mail: [email protected]

Received date: May 04, 2016; Accepted date: June 14, 2016; Published date: June 20, 2016

Citation: Sethi KK, Nayak PK, Sarkar H, Verma SM (2016) A Rational Approach towards the Development of Human Carbonic Anhydrase Inhibitors as Antiepileptic Agent. Med chem (Los Angeles) 6:405-410. doi:10.4172/2161-0444.1000377

Copyright: © 2016 Sethi KK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Medicinal Chemistry

Abstract

Antiepileptic activity study considering the MES model and molecular docking studies were performed for a series of previously synthesized dioxoisoindolin benzene sulfonamide derivatives. The reported molecules were investigated as inhibitors of the zinc metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1), specifically against the hCA I and II isoforms. To get a better insight of these molecules as potential inhibitors we specifically consider the hCA I (Ki values in the range 159 nM to >10000 nM) and hCAII (Ki values in range 1.7 nM to >10000 nM). The most potential molecule explored in the study was 3-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)benzenesulfonamide (Ki=27.7 nM), 3-chloro-4-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)benzenesulfonamide(Ki=4.9 nM) and 4-((4-nitro-1,3-dioxoisoindolin-2-yl)methyl)benzenesulfonamide (Ki=34 nM) respectively with obtained p-value <0.01 in the MES study and showed higher antepileptic activity than acetazolamide (AZM). Moreover a well defined docking score with RMSD value of 1.8 throws light on their effective binding to the active site of both 1AZM and 1ZFQ respectively.

Keywords

Carbonic anhydrase inhibitors; Sulfonamide; Docking; Anti-epilepsy

Abbreviations

CA: Carbonic Anhydrase; hCA: Human Carbonic Anhydrase; CAI: Carbonic Anhydrase Inhibitor; Zn: Zinc; AZM: Acetazolamide; MZA: Methazolamide; EZA: Ethoxzolamide; DCP: Dibromophenamide; DZA: Dorzolamide; BRZ: Brinzolamide; BZA: Benzolamide; TPM: Topiramate; ZNS: Zonisamide; SLP: Sulpiride; IND: Indisulam; COX: Cyclo-Oxygenase Enzyme; CLX: Celecoxib; VLX; Valdecoxib; CNS: Central Nervous System; PDB: Protein Data Bank; XP: Extra Precision; RMSD: Root Mean Square Deviation; HIS: Histidine; ASN: Asparagines; GLN: Glutamine; THR: Threonine; TRP: Tryptophan; nM: Nanomolar; mM: Milimolar.

Introduction

Carbonic anhydrases (CAs) are zinc (Zn+2) metalloenzymes present in almost all living organism with are five genetically distinct CA families α-, β-, γ-, δ- and ζ-CA’s [1-3]. Human CAs (hCAs) all belong to the α-family and are present in fifteen isoforms, which differ by molecular features, oligomeric arrangement, cellular localization, distribution in organs and tissues, expression levels, and kinetic properties. CA which catalyze the interconversion between carbon dioxide and bicarbonate and involved in other physiological processes connected with respiration and transport of CO2 or bicarbonate ion, CO2 homeostasis, electrolyte secretion in many tissues, biosynthetic reactions, calcification, etc. Inhibition and activation of these enzymes are well understood processes, with most classes of inhibitors binding to the metal centre, and activators binding at the entrance of the active site cavity [1-3].

Several studies demonstrated important roles of hCAs in a variety of physiological processes, and showed that abnormal levels or activities of these enzymes have been often associated with different human diseases.2 In the last few years, several CA isozymes have become interesting targets for the design of inhibitors or activators with biomedical applications [4-7]. Indeed originally hCA inhibitors (hCAIs) were clinically used as diuretic [4], antiglaucoma [5], and antiepileptic [6-9], whereas their employment as antiobesity drugs [10,11] or in the management of hypoxic tumors [12-14] were only recently validated. Well known clinically used hCAIs are Acetazolamide AAZ, Methazolamide MZA, Ethoxzolamide EZA, Dorzolamide DZA, Brinzolamide BRZ, Benzolamide BZA, Topiramate TPM, Zonisamide ZNS, Sulpiride SLP and Indisulam IND are best known sulfonamide and its bio-isosters as antiepileptic drug (Figure 1) [1-14].

medicinal-chemistry-Established-clinically

Figure 1: Established clinically used hCAIs[1-14].

However, because of the large number of hCA isoforms, there is a constant need to improve the inhibition and selectivity profile of the so far developed CAIs, in order to avoid side effects due to inhibition of isoforms not involved in a certain pathology [1-3].

Epilepsy is a chronic neurological disorder characterized by seizures generated by the sudden, massive, synchronous excitation of neurons in the brain [6-9]. Beside the ability to block the voltage Na+-channel, to potentiate GABAergic transmission and to block the kainate/AMPA receptor, TPM occupies a particular place among new anticonvulsants due to its ability to inhibit hCA. The enzyme, catalyzing the interconversion of CO2 and HCO3 is quite abundant in the brain, being present in the glia and neurons, mainly as the cytosolic isozymes hCA II, VII and the membrane-bound isoform hCA XIV. Although their function in the brain was not well established, it is known that these proteins are involved in the secretion of cerebrospinal fluid (CSF), being present in the choroid plexus of vertebrates in high amount. Epithelial cells of the choroid plexus possess CA II, III, XII, CA VIII and CA XI (Figure 2) [8]. It also has been proven that inhibition of the brain hCAs increases the cerebral blood flow with the concomitant raising of the CO2 partial pressure. hCA inhibition might serve as an anticonvulsant mechanism (at least in some forms of epilepsy), taking into account that the contribution of HCO3 - current to the ionic current through γ-amino butyric acid (GABAA) receptors on dendrites is increased during periods of high-frequency receptor activation. The excitatory effect of HCO3 is blocked by membrane permeate CA inhibitors [8,9,15-17].

medicinal-chemistry-Schematic-localization

Figure 2: Schematic localization of CA isozymes in the choroid plexus within CNS. Epithelial cells of the choroid plexus possess CA II, III, XII, and CA related protein (CARP) VIII and XI. CA IV is located in endothelial cells of blood vessels. Astrocytes express both CA V and CARP XI; CARP X is present in the myelin sheath. CA II is also expressed in oligodendrocytes. Neurons contain CA V, XIV, and CARP XI. The presence of CA III and CA XII was demonstrated in the rat, whereas CARP X, XI, and CA XIV were observed in the mouse[8].

Generally, the lipophilicity of compounds improve brain penetration of the drug, so that MZA or the lipophilic tert-butoxy carbonyl derivative of acetazolamide tBOC-AZA are more effective as anticonvulsants than acetazolamide, which is very hydrophilic [9].

The high lipophilicity of the best hCA inhibitors was hoped to be propitious with the crossing of the blood-brain barrier. Some of the synthesized sulfonamide derivatives by our groups [18-20] (Table 1) showed inhibitory potency against two hCA isozymes(hCA I and II) and expected to be in various important physiological processes, of the same order of magnitude as the clinically used drugs acetazolamide and methazolamide. The anticonvulsant activity of some of the best hCA inhibitors were evaluated in maximal electroshock (MES) method in mice [1,2].

Comp. code Ki (nM)* Docking Score (Glide XP) Hydrophilic/Lipophilic balance
hCA I hCA II 1AZM 1ZFQ QPlogPo/w
1 432 68 -5.6 -4.7 1.956
2 251 71 -6.0 -4.7 2.708
3 185 80 -6.1 -4.8 2.378
4 340 79 -5.8 -5.2 1.982
5 >10000 190 -3.9 -4.8 2.189
6 332 7.1 -5.8 -4.5 2.121
7 427 5.2 -5.3 -4.5 2.373
8 326 2.9 -6.1 -4.6 2.455
9 444 27.7 -5.9 -5.1 2.193
10 >10000 4515 -4.1 -3.8 2.955
11 368 3.4 -5.9 -4.7 2.622
12 159 4.9 -5.8 -4.6 2.220
13 281 2.4 -6.1 -4.6 2.423
14 318 4.3 -5.6 -5.1 2.597
15 403 238 -5.9 -4.6 2.683
16 295 589 -6.0 -5.5 2.194
17 501 887 -5.7 -4.7 -0.403
18 >10000 >10000 -3.7 -3.8 0.333
19 490 34 -5.8 -5.1 0.014
20 522 3.9 -5.9 -5.1 -0.363
21 >10000 1.7 -3.8 -4.7 -0.038
22 9600 35 -5.9 -5.1 -0.403
23 620 25 -5.9 -4.7 0.152
24 380 11 -6.1 -5.7 -0.227
25 11600 162 -5.9 -5.2 0.064
26 8500 79 -4.4 -5.6 2.475
AAZ 250 12 -4.8 -3.8 0.455

Table 1: hCA I and II inhibition data with sulfonamides 1-26, standard AZM and other important CAIs, by a stopped-flow CO2 hydrase assay method, docking score and hydrophilic/lipophilic balance.

Experimental

Anti-epileptic study

Animals: All procedures described here were approved by the Institutional Animal Ethics Committee (Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, India) and conducted in accordance with guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment and Forests, Government of India. Male albino mice (20-25 g) were obtained from Chakraborty Enterprises, Kolkata, India and acclimatized in the Institute’s Animal House for one week. Animal house had 12:12 hr light and dark cycle (temperature 22 ± 2°C, relative humidity of 30 to 70%) and mice had free access to standard rodent food and tap water.

MES-induced seizures: The maximal electroshock (MES) is a useful tool for assessing generalized tonic-clonic (grand mal) seizures [21]. Corneal stimulation produces a preferential activation of the forebrain structures, while stimulation through ear-clip electrodes activates the brain stem. In mice, MES-induced seizures consist of initial tonic flexion, then hind limb tonic extension (HLTE), followed by the stage of clonus and terminal stupor [22].

On the day of experimentation animals were randomized into groups of 5 mice each in separate labeled cages for control (0.1% Tween 80), test compounds (100 mg/kg) and standard drugs (AZM and phenytoin; 25 mg/kg). After 30 min of intraperitoneal vehicle or drug administration (10 ml/kg), maximal electroshock was delivered to all animals by a rodent electroconvulsiometer through ear clip electrodes. Seizure was induced by passing alternating current of 45 mA for 0.2 sduration. Animals were observed closely for 2 min for duration and end of HLTE which was the measure of seizure prevention efficacy. The number of animal did not show HLTE and died in a particular group within 24 h was used to calculate percentage protection and percentage mortality, respectively [22].

Statistical analysis: Results were expressed as mean values ± SEM. One-way analysis of variance (ANOVA) was used for statistical comparison followed by post-hoc Newman-Keuls Multiple Comparison test and P<0.05 was considered to be significant difference.

Docking studies

Molecular docking studies were performed in Maestro Glide v 8.5.111 (of Schrödinger) installed in a single machine running with Red Hat Linux Enterprise version 5.0 as the operating system. The ligands were built and adjusted by means of Maestro 8.5.111.

Best pose of each ligand was ranked according to the E-model energy. The docking score from Glide (Glide Score) is entirely based on Chem Score (Equation 15). It also includes a steric-clash term, adds polar terms featured by Schrodinger to correct electrostatic mismatches [23-26].

GScore=0.065 × van der Waals energy+0.130 × Coulomb energy+Lipophilic term (Hydrophobic interactions)+H bonding+Metal binding+BuryP (Penalty for buried polar groups)+RotB (Penalty for freezing rotatable bonds)+Site (Polar interactions in the active site)

The best docked conformation is similar to the crystal structure conformation of AZM and superimposes with root mean square deviation (RMSD) of 1.5 Å, indicating that GLIDE is reliable software for docking of inhibitors into hCA II.

Results and Discussion

hCA inhibition studies

The hCA inhibition on cytosolic hCA I and II data of compounds 1-26 (Figure 3), the standard AZM and other clinically used sulfonamides are shown in Table 1 [2,16-19].

medicinal-chemistry-Synthesized-dioxoisoindolin

Figure 3: Synthesize ddioxoisoindolin benzene sulfonamide derivatives of hCAIs[16-19].

Anti-epileptic study

The anti-epileptic activity of the synthesized novel hCAIs was studied using mice model of MES-induced seizure at 100 mg/ kg intraperitoneal dose and findings are presented in Table 2. All compounds from tetrabromo-1,3-dioxoisoindolin benzenesulfonamide series caused reduction in duration of HLTE (hind limb tonic extension), but a significant decrease was observed with compound 5 (P<0.01) in which two out of five animals did not show HLTE.

Treatment Dose % Protection % Mortality HLTE (in Sec)
Tween 80 (0.1%) 10 ml/kg 0 40 17 ± 3.24
1 100 mg/kg 20 0 8.4 ± 5
2 0 0 11 ± 5.1
3 0 20 13 ± 2.2
4 0 0 12 ± 1.6
5 40 0 5.4 ± 5.4**
6 0 20 14.2 ± 0.8
7 60á´ª 0 5 ± 6.9**
8 0 0 11.6 ± 1.1
9 60á´ª 0 4.4 ± 6.4***
10 0 0 11 ± 1.4
11 20 0 8.4 ± 4.8
12 40 0 6.4 ± 5.9**
13 20 0 9.8 ± 5.8
14 0 0 14.4 ± 2.1
15 0 0 14.4 ± 2.7
16 100á´ª 0 0 ± 0***
17 0 0 14.6 ± 1.1
18 40 0 7.6 ± 7.0*
19 60á´ª 0 3.8 ± 5.2***
20 0 0 11 ± 1.6
21 0 0 14.2 ± 2.2
22 60á´ª 0 4.4 ± 6.1***
23 40 0 6.4 ± 5.9**
24 100á´ª 0 0 ± 0***
25 100á´ª 0 0 ± 0***
26 100á´ª 0 0 ± 0***
AZM 25 mg/kg 20 0 8.0 ± 2.2*
Phenytoin 25 mg/kg 100á´ª 0 0 ± 0***

Table 2: Effect of novel hCAIs and standard drugs against MES-induced seizure in mice.

Three derivatives from tetrachloro-1,3-dioxoisoindolin benzenesulfonamide series, compound 7 (P<0.01), 9 (P<0.001) and 12 (P<0.01) demonstrated significant attenuation of HLTE with no tonic extension in up to 60% of animals. Compound 16 (P<0.01) and 18 (P<0.05) produced significant reduction in HLTE duration whereas a minor decrease was observed with other compounds in the same series. All compounds from 19-21 attenuated seizure activity in mice, but compound 19 protected 60% of animals against tonic extension and showed significant (P<0.001) reduction in HLTE duration. Correspondingly, all compounds from 22-26 established significantdecrease in HLTE duration while protecting up to 100% of the tested animals. Similarly, standard drugs (AZM) at 25 mg/ kg intraperitoneal dose significantly reduced MES-induced tonic extension while protecting 20, 40, and 80% of animals, respectively. Finally, it was evident that the protective effect produced by compound 16, 24, 25, and 26 against MES-induced seizure was comparable to that of AZM (25 mg/kg, i.p.) and phenytoin (25 mg/kg, i.p.).

Docking studies

Molecular docking of twenty six compounds and other clinically used sulfonamides were performed (Table 1) in order to find out the binding mode analysis (Figure 4). Docking was performed preferably by interest in crystal structure of hCA preferably in 1AZM (hCA I) and 1FZQ (hCA II) [27,28]. All the ‘A’ chain of the crystal structures catalytic domains of the hCA was considered for docking. The Glide (XP) score of the co-crystalliged ligand AZM is -3.8 to -4.8 and the RMSD values is 1.8 which is considered as good for docking of the ligands (Table 1). Most of the docking scores of the synthesized compounds are so good enough then standard AZM and other clinically used hCAI. Figure 4 has shown the docked conformations of compound 24, one of the highest docking score compound in catalytic binding pocket of hCA I and II.

medicinal-chemistry-Docked-conformations

Figure 4: Docked conformations of compound 24 in the catalytic Zn binding pocket of hCA,(a) hCAI (1AZM) binding pocket formed H-bond to HIS 90, HIS 200, GLN 92; (b) hCA II(1ZFQ) formed hydrogen bond to GLN 92.

The hydrophilic/lipophilic balance has been evaluated by the Schrödinger from Qikprop. QP log Po/w: Predicted octanol /water partition coefficient are with the range limit of -2.0 to 6.5 which predicts the compounds to have good cell permeability.

Conclusions

Antiepileptic activity study considering the MES model and molecular docking studies was performed for a series of previously synthesized dioxoisoindolin benzene sulfonamide derivatives and shown a better insight of these molecules as potential inhibitors we specifically consider the hCA I (Ki values in the range 159 nM to >10000 nM) and hCAII (Ki values in range 1.7 nM to >10000 nM). The most potential molecule explored in the study was 3-(4,5,6,7-tetrachloro-1,3- dioxoisoindolin-2-yl)benzenesulfonamide (Ki=27.7 nM), 3-chloro- 4-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)benzenesulfonamide (Ki=4.9 nM) and 4-((4-nitro-1,3-dioxoisoindolin-2-yl)methyl) benzenesulfonamide (Ki=34 nM) respectively with obtained p-value <0.01 in the MES study and showed higher antepileptic activity than acetazolamide (AZM). Moreover, the data from anticonvulsant study showed significant protection against MES-induced seizure which further validates a relationship between hCA inhibitors and anti-epileptic activity. Some of the derivatives did not produce marked antiepileptic activity in spite of their CA inhibitor activity. This mismatch could be due to differences in pharmacokinetics as optimum blood-brain permeability is required for any drug to produce therapeutic effect in the central nervous system. The MES seizures induced by transauricular stimulation are more severe and hard to inhibit with anti-epileptic drugs as compared to MES elicited with transcorneal electrodes, due to involvement of the brain stem. However, several compounds in this study abolished all components of generalized tonic-clonic seizures suggesting higher potency that was comparable with MZA and phenytoin. Moreover a well-defined docking score with RMSD value of 1.8 throws light on their effective binding to the active site of both 1AZM and 1ZFQ respectively.

Acknowledgements

This work is acknowledged to our Vice-chancellor of BIT Mesra, Ranchi who has given all the infrastructural opportunity for research. I am greatly indebted to Dr CT Supuran for the enzyme assay.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 9731
  • [From(publication date):
    June-2016 - Nov 17, 2019]
  • Breakdown by view type
  • HTML page views : 9587
  • PDF downloads : 144

Review summary

  1. Khayriyyah
    Posted on Sep 30 2016 at 3:42 pm
    The article studies the anti-epileptic effects of human carbonic anhydrase inhibitors using mice model of MES-induced seizure. The study has interest but it needs a deep review.

Post your comment

captcha   Reload  Can't read the image? click here to refresh
Peer Reviewed Journals

Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals

Top